Market cap
$1.23B

Inhibrx Biosciences Inc. (INBX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for INBX, including 3 SEC filings, 1 press release or news item and 1 earnings update. The most recent was published Nov 13, 2026.

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.

INBX rankings

Financial highlights

Full financials
Revenue, TTM
$2.00M
Revenue growth
+42.9%
Net income, TTM
-$141.66M
Net margin
-7082.9%
Free cash flow, TTM
-$132.70M
Cash
$199.47M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks44+50%
2026-05-24: 02026-05-31: 52026-06-07: 02026-06-14: 22026-06-21: 02026-06-28: 02026-07-05: 02026-07-12: 22026-07-19: 02026-07-26: 02026-08-02: 12026-08-09: 42026-08-16: 02026-08-23: 12026-08-30: 12026-09-06: 92026-09-13: 82026-09-20: 12026-09-27: 22026-10-04: 02026-10-11: 22026-10-18: 02026-10-25: 12026-11-01: 02026-11-08: 52026-11-15: 0
2026-05-242026-11-15
Mix3090d
  • Insider13(43%)
  • SEC Filings10(33%)
  • Other3(10%)
  • Earnings2(7%)
  • Analyst1(3%)
  • 13D/G1(3%)
Activity · 52 weeks6737 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

INBX FAQ

10 questions
  • What does Inhibrx Biosciences Inc. do?
    Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein...
  • What is the latest news on INBX?
    In the last 30 days Quantisnow tracked 6 wire items for INBX: 3 SEC filings, 1 press release or news item, 1 earnings update and 1 13D/G filing. The most recent was published on November 13, 2026.
  • What is INBX revenue?
    Inhibrx Biosciences Inc. (INBX) reported $2.00M of revenue for the twelve months ended Sep 30, 2026. That is up 42.9% from the year before. Revenue for fiscal 2025 was $1.30M.
  • Is INBX profitable?
    No. Inhibrx Biosciences Inc. reported a net loss of $141.66M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does INBX have?
    Inhibrx Biosciences Inc. reported $199.47M in cash and cash equivalents and $276.70M of debt on its most recent balance sheet in SEC filings.
  • Where does INBX stock trade?
    Inhibrx Biosciences Inc. (INBX) is listed on NASDAQ.
  • What sector and industry is INBX in?
    Inhibrx Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • What are analysts saying about INBX?
    Across the last 8 analyst actions on Inhibrx Biosciences Inc., there were 0 upgrades and 1 downgrade. The most recent action was from H.C. Wainwright: Buy with a $245.00 price target on 2026-08-24.
  • What companies are similar to INBX?
    Notable peers in the same industry include RVMD (Revolution Medicines Inc.), MRNA (Moderna Inc.), AMGN (Amgen Inc.), ARGX (argenx SE), GILD (Gilead Sciences Inc.). Compare INBX side-by-side with any of them on Quantisnow.
  • How can I track INBX on Quantisnow?
    Quantisnow aggregates Inhibrx Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INBX to receive live email and push alerts on every new disclosure.